$2.12
1.40% yesterday
Nasdaq, Jun 13, 10:09 pm CET
ISIN
US05280R1005
Symbol
AUTL
Sector
Industry

Autolus Therapeutics plc Stock price

$2.12
+0.85 66.93% 1M
-0.37 14.86% 6M
-0.23 9.79% YTD
-2.41 53.20% 1Y
-10.88 83.69% 5Y
-22.88 91.52% 10Y
-22.88 91.52% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.03 1.40%
ISIN
US05280R1005
Symbol
AUTL
Sector
Industry

Key metrics

Market capitalization $572.20m
Enterprise Value $309.06m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 34.30
P/S ratio (TTM) P/S ratio 63.51
Revenue growth (TTM) Revenue growth -14.19%
Revenue (TTM) Revenue $9.01m
EBIT (operating result TTM) EBIT $-208.75m
Free Cash Flow (TTM) Free Cash Flow $-283.85m
Cash position $516.58m
EPS (TTM) EPS $-0.68
P/E forward negative
P/S forward 10.09
EV/Sales forward 5.45
Short interest 5.73%
Show more

Is Autolus Therapeutics plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Autolus Therapeutics plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Autolus Therapeutics plc forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Autolus Therapeutics plc forecast:

Buy
100%

Financial data from Autolus Therapeutics plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
9.01 9.01
14% 14%
100%
- Direct Costs 29 29
-
326%
-20 -20
-
-226%
- Selling and Administrative Expenses 91 91
63% 63%
1,005%
- Research and Development Expense 98 98
25% 25%
1,086%
-201 -201
19% 19%
-2,226%
- Depreciation and Amortization 8.19 8.19
27% 27%
91%
EBIT (Operating Income) EBIT -209 -209
19% 19%
-2,317%
Net Profit -180 -180
19% 19%
-1,996%

In millions USD.

Don't miss a Thing! We will send you all news about Autolus Therapeutics plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Autolus Therapeutics plc Stock News

Neutral
GlobeNewsWire
2 days ago
Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow up More than half of patients still in remission at 24 months 38% of ongoing responders did not receive any subsequent therapy by month 33 Results suggest a proportion of patients with r/r B-ALL may not need further therapy following treatment with obe-cel LONDON, June 12, 2025 (GLOBE NEWSWIRE) --...
Positive
Seeking Alpha
8 days ago
Autolus Therapeutics plc is a UK-based biotech that has brought its ex-vivo CAR-T cell therapy to market in B-ALL with a "best-in-class" safety/efficacy profile. In this small indication, peak revenues may be no more than $200 - $300m, but the drug's launch has been successful, with $9m earned in Q1 2025. Autolus plans to share more data from its FELIX study imminently, which could open up appr...
Neutral
GlobeNewsWire
16 days ago
LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in upcoming investor conferences. William Blair 45 th Annual Growth Stock Conference Management to host investor meetingsDate: June 3...
More Autolus Therapeutics plc News

Company Profile

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Christian Itin
Employees 649
Founded 2014
Website www.autolus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today